{ "schemaVersion": 2, "eyebrow": "Psychiatry", "title": "Bipolar Disorder", "summary": "Bipolar disorder requires longitudinal diagnostic assessment and phase-specific treatment. Prioritize recognition of past mania or hypomania in depressed patients, manage acute episodes with mood stabilizers or antipsychotics, and sustain relapse prevention through individualized maintenance medication, psychosocial care, and safety monitoring.", "seoDescription": "Physician guide to longitudinal diagnosis and phase-specific pharmacologic and maintenance management of bipolar disorder in adults.", "clinicalQuestion": "How should clinicians confirm bipolar disorder and select phase-specific acute and maintenance treatment?", "specialty": "Psychiatry", "audience": "U.S. physicians and medical trainees", "tags": [ "bipolar I disorder", "bipolar II disorder", "mania", "bipolar depression", "mood stabilizers", "maintenance treatment" ], "keyTakeaways": [ "Diagnosis depends on a comprehensive current mental-status assessment plus longitudinal history obtained from the patient and family; depressive disorders are a frequent source of misdiagnosis.[4]", "Acute mania and maintenance management require a mood stabilizer or antipsychotic, alone or in combination; antidepressant monotherapy is not indicated for bipolar disorder.[4]", "Quetiapine extended release is FDA-labeled for bipolar depressive episodes at 300 mg/day after a 4-day titration and for bipolar I maintenance adjunctive to lithium or divalproex at 400-800 mg/day.[2]", "Lamotrigine is FDA-indicated for maintenance treatment of bipolar I disorder after acute mood stabilization, but is not recommended for acute manic or mixed episodes and has not established efficacy for acute mood episodes.[3]" ], "sections": [ { "id": "diagnostic-assessment", "eyebrow": "Diagnosis", "heading": "Establish the longitudinal mood-episode diagnosis", "intro": "Do not diagnose or exclude bipolar disorder from the current depressive presentation alone.", "paragraphs": [ "Diagnostic assessment should integrate the mental-status examination with a longitudinal account of mood episodes, including collateral history from family when available.[4] In patients presenting with depression, actively seek prior manic or hypomanic episodes because unipolar depressive disorders are a common diagnostic misclassification.[4]", "Screening instruments can improve recognition but do not replace diagnostic assessment. The Mood Disorder Questionnaire is widely used; one tertiary mental-health study reported sensitivity of 66% (95% CI, 57%-73%) and specificity of 86%.[16] A positive screen should trigger a structured clinical history rather than establish the diagnosis." ], "bullets": [ "Clarify episode polarity, severity, frequency, interepisode symptoms, prior treatments and responses, functional consequences, and associated risk.[6]", "Assess substance use, medication adherence, potential relapse triggers, early warning signs, and self-management strategies before attributing nonresponse to pharmacologic failure.[6][15]", "Differentiate recurrent episodic mood change from affective instability associated with other conditions; this distinction has direct treatment implications.[20]" ], "subsections": [], "table": { "caption": "High-yield diagnostic inputs and their practical use.[4][6][16]", "columns": [ "Input", "Clinical use" ], "rows": [ [ "Current mental-status examination", "Characterize present mood state, psychosis, behavioral activation, impairment, and immediate risk as part of the diagnostic assessment.[4]" ], [ "Longitudinal patient and collateral history", "Identify prior manic, hypomanic, depressive, or mixed episodes and establish illness course; include family input when available.[4]" ], [ "Mood Disorder Questionnaire", "Use as a case-finding aid, not a diagnostic test; reported sensitivity was 66% and specificity 86% in one tertiary setting.[16]" ], [ "Treatment and relapse history", "Review prior response, adherence, episode severity and frequency, triggers, and early warning signs to guide treatment selection and relapse planning.[6]" ] ] } }, { "id": "acute-mood-episodes", "eyebrow": "Acute treatment", "heading": "Match treatment to episode polarity", "intro": "Acute treatment choice should be driven by mania, depression, mixed features, severity, and prior response.", "paragraphs": [ "For acute mania, mood stabilizers and antipsychotics are core therapies, used as monotherapy or in combination.[4] Antipsychotics are effective for acute mania, whereas their efficacy for depression varies by agent.[8] Lithium remains a first-line option for mania in many contemporary guidelines, either alone or in combination.[15]", "For moderate or severe bipolar depression in a patient not receiving a bipolar medication, NICE-based guidance supports quetiapine monotherapy or fluoxetine combined with olanzapine.[6] Quetiapine and olanzapine-fluoxetine combination have evidence for bipolar depression in systematic review evidence.[21] Traditional antidepressants alone are not indicated in bipolar disorder.[4]", "When a first-line antimanic agent at therapeutic dose has not produced sufficient response after 1-2 weeks, reassess dose optimization, adherence, and substance use before considering combination treatment.[15] This interval is guidance cited in a review of contemporary guideline recommendations rather than a patient-specific mandate." ], "bullets": [ "Choose treatment with the anticipated maintenance strategy in view; acute stabilization is only one component of recurrent-illness care.[5]", "For bipolar depression, monitor for emergent mania or hypomania and for worsening depressive symptoms during pharmacologic and psychological treatment.[6]", "Escalate care based on acute safety, behavioral disturbance, psychosis, inability to maintain self-care, and need for intensive monitoring; the supplied sources do not provide operational thresholds for site-of-care decisions." ], "subsections": [ { "heading": "Quetiapine extended-release dosing in FDA labeling", "paragraphs": [ "For adults with bipolar depressive episodes, the extended-release quetiapine label specifies 50 mg/day on day 1, 100 mg/day on day 2, 200 mg/day on day 3, and 300 mg/day on day 4, followed by 300 mg/day.[2] For adult bipolar I maintenance adjunctive to lithium or divalproex, labeled dosing is 400-800 mg/day.[2]" ], "bullets": [ "In a 3-week placebo-controlled bipolar mania study of extended-release quetiapine, commonly observed adverse reactions occurring at least twice the placebo rate included somnolence (50% vs 12%), dry mouth (34% vs 7%), dizziness (10% vs 4%), constipation (10% vs 4%), and weight gain (7% vs 3%).[2]", "The available FDA-label excerpt is from 2017; verify the current product-specific U.S. prescribing information before prescribing.[2]" ] } ], "table": { "caption": "Phase-specific pharmacologic options supported by the supplied evidence.[2][3][4][6][8][15][21]", "columns": [ "Clinical phase", "Supported approach", "Important limitation or tradeoff" ], "rows": [ [ "Acute mania", "Use a mood stabilizer or antipsychotic as monotherapy or in combination; lithium is a first-line option in many guidelines.[4][15]", "Before adding therapy after inadequate response, address dose, adherence, and substance use.[15]" ], [ "Bipolar depression", "Quetiapine monotherapy or olanzapine-fluoxetine combination are supported options in cited guidance and review evidence.[6][21]", "Antidepressant monotherapy is not indicated; monitor for mood switching or clinical deterioration.[4][6]" ], [ "Bipolar I maintenance", "Consider ongoing medication after acute stabilization; quetiapine XR is labeled adjunctively with lithium or divalproex at 400-800 mg/day.[2]", "Periodically reassess need for maintenance therapy.[2]" ], [ "Lamotrigine use", "Use for FDA-indicated maintenance treatment of bipolar I disorder to delay mood episodes after treatment of acute episodes with standard therapy.[3]", "Do not use as treatment for acute manic or mixed episodes; acute mood-episode efficacy has not been established in the label.[3]" ] ] } }, { "id": "maintenance-and-relapse-prevention", "eyebrow": "Long-term care", "heading": "Treat relapse prevention as the central management objective", "intro": "Maintenance planning should begin during acute stabilization and be revisited after every episode.", "paragraphs": [ "Bipolar disorder is recurrent; a cited review reports typical recurrence every 17-30 months, underscoring the need to reduce both manic and depressive relapse rather than merely terminate the index episode.[5] Long-term management should individualize medication, adjunctive psychosocial therapy, monitoring for treatment-emergent complications, and health behaviors including sleep hygiene, exercise, and stress management.[4]", "Lithium and valproate are both recommended monotherapies for relapse prevention in the source trial background.[12] Lithium and quetiapine are described in a review of guideline evidence as agents with level 1 evidence for prevention of both manic and depressive episodes.[15] Selection should incorporate prior episode polarity, treatment response, adverse-effect burden, reproductive plans, comorbidity, and feasibility of monitoring." ], "bullets": [ "Discuss the expected benefits and risks of long-term treatment, relapse after dose reduction or discontinuation, and the need to monitor mood and medication effects.[6]", "Review pregnancy intentions before medication changes; teratogenic concerns require treatment review in people planning pregnancy.[5][6]", "Medication adverse effects may persist into maintenance and some clinically important toxicities emerge only with longer-term exposure; use agent-specific monitoring schedules.[5]", "Offer a bipolar-specific psychological intervention with an evidence-based manual, or a high-intensity intervention such as cognitive behavioral therapy, interpersonal therapy, or behavioral couples therapy when appropriate.[6]" ], "subsections": [], "table": { "caption": "Maintenance decisions that should be explicitly revisited.[2][3][5][6]", "columns": [ "Decision", "Action" ], "rows": [ [ "Need for ongoing therapy", "Periodically reassess the need for maintenance treatment while accounting for recurrent illness course and prior relapse burden.[2][5]" ], [ "Medication tolerability", "Monitor medication-specific adverse effects and toxicity; some adverse effects persist and some become evident only with long-term treatment.[5]" ], [ "Stopping or reducing therapy", "Discuss relapse risk, expected benefits and harms, and monitor mood closely when treatment changes are contemplated.[6]" ], [ "Psychosocial relapse prevention", "Use bipolar-specific or high-intensity psychological interventions alongside medication when clinically appropriate.[6]" ] ] } }, { "id": "medication-selection-cautions", "eyebrow": "Prescribing cautions", "heading": "Avoid polarity-treatment mismatches", "intro": "The highest-value prescribing error is using an agent outside its evidence-supported role for the current phase.", "paragraphs": [ "Lamotrigine is indicated for bipolar I maintenance to delay mood episodes in patients treated for acute mood episodes with standard therapy.[3] Its label specifically states that treatment of acute manic or mixed episodes is not recommended and that effectiveness for acute mood episodes has not been established.[3] Do not infer acute antimanic efficacy from its maintenance indication.", "Quetiapine has phase-specific labeled dosing and clinically meaningful sedating and metabolic adverse effects in trial data.[2] Somnolence, dry mouth, dizziness, constipation, and weight gain should influence dose titration, counseling, fall-risk assessment, and follow-up planning.[2]" ], "bullets": [ "Do not treat a positive bipolar screening result as confirmation; obtain a longitudinal episode history and collateral information when possible.[4][16]", "Do not use traditional antidepressants alone for bipolar disorder.[4]", "Do not assume all antipsychotics have equivalent efficacy for bipolar depression; available evidence describes variable antidepressant efficacy across agents.[8]" ], "subsections": [], "table": { "caption": "Common treatment errors and corrective actions.[2][3][4][8][16]", "columns": [ "Potential error", "Corrective action" ], "rows": [ [ "Labeling recurrent depression as unipolar without probing for prior activation", "Obtain longitudinal patient and family history and use screening tools only as adjuncts to diagnostic assessment.[4][16]" ], [ "Using antidepressant monotherapy", "Use a bipolar-specific pharmacologic strategy; traditional antidepressants alone are not indicated.[4]" ], [ "Using lamotrigine for acute mania", "Select an antimanic treatment instead; lamotrigine is not recommended for acute manic or mixed episodes.[3]" ], [ "Ignoring quetiapine adverse effects during titration", "Anticipate somnolence, dry mouth, dizziness, constipation, and weight gain, and adjust monitoring and counseling accordingly.[2]" ] ] } } ], "faq": [ { "question": "Should the Mood Disorder Questionnaire be used to diagnose bipolar disorder?", "answer": "No. It may improve case finding, but diagnosis requires comprehensive clinical assessment, current mental-status examination, and longitudinal patient and collateral history. One cited study reported sensitivity of 66% and specificity of 86%.[4][16]" }, { "question": "Is lamotrigine appropriate for acute mania?", "answer": "No. FDA labeling states that lamotrigine is not recommended for acute manic or mixed episodes and that acute mood-episode effectiveness has not been established. Its bipolar indication is maintenance treatment of bipolar I disorder after acute stabilization.[3]" }, { "question": "What is the labeled quetiapine extended-release dose for adult bipolar depression?", "answer": "The supplied FDA label specifies 50 mg/day on day 1, 100 mg/day on day 2, 200 mg/day on day 3, and 300 mg/day on day 4, then 300 mg/day.[2]" }, { "question": "When should combination treatment be considered for mania?", "answer": "A review of guideline recommendations suggests considering combination treatment after insufficient response following 1-2 weeks at therapeutic doses of a first-line antimanic agent, after dose optimization and assessment of adherence and substance use.[15]" } ], "references": [ { "number": 1, "title": "2970592 This label may not be the latest approved by FDA ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020639s049s054lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 2, "title": "quetiapine fumarate extended-release tablets", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/090482Orig1s000lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 3, "title": "These highlights do not include all the information needed to use LAMOTRIGINE TABLETS and LAMOTRIGINE TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS and LAMOTRIGINE TABLETS FOR ORAL SUSPENSION.

LAMOTRIGINE tablets, for oral use
LAMOTRIGINE tablets for oral suspension
Initial U.S. Approval: 1994", "detail": "nctr-crs.fda.gov", "url": "https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/15d801a0-f0a5-40c1-bc88-d5ba9a02c696/spl-doc", "authors": "nctr-crs.fda.gov", "host": "nctr-crs.fda.gov" }, { "number": 4, "title": "Bipolar disorder in adults - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/488", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 5, "title": "Maintaining mood stability in bipolar disorder", "detail": "mentalhealth.bmj.com", "url": "https://mentalhealth.bmj.com/content/18/1/1.full.pdf", "authors": "mentalhealth.bmj.com", "host": "mentalhealth.bmj.com" }, { "number": 6, "title": "Assessment and management of bipolar disorder", "detail": "www.bmj.com", "url": "https://www.bmj.com/bmj/section-pdf/765723?path=%2Fbmj%2F349%2F7976%2FPractice.full.pdf", "authors": "www.bmj.com", "host": "www.bmj.com" }, { "number": 7, "title": "Drug treatments for bipolar disorder: 1 - Acute manic or depressive | Drug and Therapeutics Bulletin", "detail": "dtb.bmj.com", "url": "https://dtb.bmj.com/content/43/4/28", "authors": "dtb.bmj.com", "host": "dtb.bmj.com" }, { "number": 8, "title": "Treatment of bipolar disorder", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60857-0/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 9, "title": "Drug treatments for bipolar disorder: 2 - Maintenance, prevention and special situations | Drug and Therapeutics Bulletin", "detail": "dtb.bmj.com", "url": "https://dtb.bmj.com/content/43/5/33", "authors": "dtb.bmj.com", "host": "dtb.bmj.com" }, { "number": 10, "title": "Bipolar disorder", "detail": "www.bmj.com", "url": "https://www.bmj.com/bmj/section-pdf/187715?path=", "authors": "www.bmj.com", "host": "www.bmj.com" }, { "number": 11, "title": "Bipolar disorders: an update on critical aspects", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00304-1/fulltext", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 12, "title": "Lithium plus valproate combination therapy versus ...", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61828-6/fulltext", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 13, "title": "The Emerging Neurobiology of Bipolar Disorder", "detail": "www.cell.com", "url": "https://www.cell.com/trends/neurosciences/fulltext/S0166-2236(17)30212-6", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 14, "title": "From theory to practice: Revealing the real-world impact of ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)13794-2", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 15, "title": "Existing and emerging pharmacological approaches to the treatment of mania: A critical overview", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41398-022-01928-8", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 16, "title": "Screening for bipolar disorder in a tertiary mental health ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2666915321001414", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 17, "title": "Review Differential diagnosis of bipolar disorder and major ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0165032714700047", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 18, "title": "Presentation, Clinical Course, and Diagnostic Assessment of ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/book/24609/chapter/187895759", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 19, "title": "Screening for bipolar disorder in a Spanish sample of outpatients with current major depressive episode", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165032708002814", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 20, "title": "Differential diagnosis of bipolar affective disorder type II and borderline personality disorder: analysis of the affective dimension", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0010440X12000454", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 21, "title": "Treatment of bipolar disorder: a systematic review of available ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/11/7/999/787005", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 22, "title": "a CINP Task Force report based on a review of evidence", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/10/Supplement_1/S1/855835", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 23, "title": "Pharmacological Augmentation in Unipolar Depression", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/23/9/587/5836840", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 24, "title": "12 APPENDICES", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg185/documents/bipolar-disorder-update-draft-full-guideline-appendices-1102", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "2970592 This label may not be the latest approved by FDA ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020639s049s054lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "Of these approximately 4300 subjects, approximately 4000 (2300 in schizophrenia, 405 in acute bipolar mania, 698 in bipolar depression, and 646 for the maintenance treatment of bipolar I disorder) were patients who participated in multiple dose effectiveness trials, and their experience corresponded", "score": 0.5849357 }, { "number": 2, "title": "quetiapine fumarate extended-release tablets", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/090482Orig1s000lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "mg/day Bipolar I Disorder, manic-Acute monotherapy-Children and Adolescents (10 to 17 years) Day 1: 50 mg/day Day 2: 100 mg/day Day 3: 200 mg/day Day 4: 300 mg/day Day 5: 400 mg/day 400 to 600 mg/day 600 mg/day Bipolar Disorder, Depressive Episodes-Adults Day 1: 50 mg/day Day 2: 100 mg/day Day 3: 20", "score": 0.4116553 }, { "number": 3, "title": "These highlights do not include all the information needed to use LAMOTRIGINE TABLETS and LAMOTRIGINE TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS and LAMOTRIGINE TABLETS FOR ORAL SUSPENSION.

LAMOTRIGINE tablets, for oral use
LAMOTRIGINE tablets for oral suspension
Initial U.S. Approval: 1994", "detail": "nctr-crs.fda.gov", "url": "https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/15d801a0-f0a5-40c1-bc88-d5ba9a02c696/spl-doc", "authors": "nctr-crs.fda.gov", "host": "nctr-crs.fda.gov", "snippet": "externa, pharyngitis, urinary tract infection, and viral infection. Respiratory adverse reactions included nasal congestion, cough, and apnea. Bipolar Disorder Safety and efficacy of lamotrigine for the maintenance treatment of bipolar disorder were not established in a double-blind, randomized ", "score": 0.3704537 }, { "number": 4, "title": "Bipolar disorder in adults - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/488", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Diagnosis is based on a comprehensive clinical assessment, encompassing the mental status exam at the time of the evaluation and the longitudinal history from the patient and family, using diagnostic criteria for bipolar disorder.\n\nMisdiagnosis and delayed diagnosis of bipolar disorder are common, w", "score": 0.7001783 }, { "number": 5, "title": "Maintaining mood stability in bipolar disorder", "detail": "mentalhealth.bmj.com", "url": "https://mentalhealth.bmj.com/content/18/1/1.full.pdf", "authors": "mentalhealth.bmj.com", "host": "mentalhealth.bmj.com", "snippet": "INTRODUCTION Bipolar disorder is defined by its poles, elevated mood or irritability characterises mania, and marked low mood and lack of energy typifies depression. Treatment of these acute states is necessary for the patient’s well-being but the major management challenge lies in redu-cing the frequ", "score": 0.67063034 }, { "number": 6, "title": "Assessment and management of bipolar disorder", "detail": "www.bmj.com", "url": "https://www.bmj.com/bmj/section-pdf/765723?path=%2Fbmj%2F349%2F7976%2FPractice.full.pdf", "authors": "www.bmj.com", "host": "www.bmj.com", "snippet": "of bipolar disorder – – The role of psychological and pharmacological interventions to prevent relapse and reduce symptoms – – The risk of relapse after reducing or stopping drugs for an acute episode – – The potential benefits and risks of long term drugs and psychological interventions, and the ne", "score": 0.6466616 }, { "number": 7, "title": "Drug treatments for bipolar disorder: 1 - Acute manic or depressive | Drug and Therapeutics Bulletin", "detail": "dtb.bmj.com", "url": "https://dtb.bmj.com/content/43/4/28", "authors": "dtb.bmj.com", "host": "dtb.bmj.com", "snippet": "## Abstract\n\nBipolar disorder is a severe, chronic mental illness characterised by repeated episodes of mania or hypomania, depression or mixed affective states.1 Depending on the clinical context, treatment may involve drugs, psychological therapies, social interventions and/or electroconvulsive th", "score": 0.51032627 }, { "number": 8, "title": "Treatment of bipolar disorder", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60857-0/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "by JR Geddes · 2013 · Cited by 1218 — Antipsychotic drugs are effective in the acute treatment of mania; their efficacy in the treatment of depression is variable with the clearest evidence for", "score": 0.45842203 }, { "number": 9, "title": "Drug treatments for bipolar disorder: 2 - Maintenance, prevention and special situations | Drug and Therapeutics Bulletin", "detail": "dtb.bmj.com", "url": "https://dtb.bmj.com/content/43/5/33", "authors": "dtb.bmj.com", "host": "dtb.bmj.com", "snippet": "BMJ Journals\n\nBMJ Journals\n\n### Log in using your username and password\n\nDrug and Therapeutics Bulletin\n\n## \n\n## \n\n## Main menu\n\n### Log in using your username and password\n\n## You are here\n\nArticle Text\n\nDownload PDF\nLoading\n\nRelevant BNF sections: 4.2.1, 4.2.3, 4.3\n\n## Abstract\n\nIn last month's is", "score": 0.4473884 }, { "number": 10, "title": "Bipolar disorder", "detail": "www.bmj.com", "url": "https://www.bmj.com/bmj/section-pdf/187715?path=", "authors": "www.bmj.com", "host": "www.bmj.com", "snippet": "Have side effects or complications from treatment that may require a change in drugs • Are considering altering or stopping treatment", "score": 0.3399377 }, { "number": 11, "title": "Bipolar disorders: an update on critical aspects", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00304-1/fulltext", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "by V Oliva · 2025 · Cited by 195 — Standard management strategies include mood stabilizers, antipsychotics, and selective use of antidepressants, complemented by psychosocial", "score": 0.33541664 }, { "number": 12, "title": "Lithium plus valproate combination therapy versus ...", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61828-6/fulltext", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "Lithium carbonate and valproate semisodium are both recommended as monotherapy for prevention of relapse in bipolar disorder,", "score": 0.27704293 }, { "number": 13, "title": "The Emerging Neurobiology of Bipolar Disorder", "detail": "www.cell.com", "url": "https://www.cell.com/trends/neurosciences/fulltext/S0166-2236(17)30212-6", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "by PJ Harrison · 2018 · Cited by 331 — The mainstay of BD treatment is pharmacological, with lithium salts or the antiepileptic drug sodium valproate used for prophylaxis. Antipsychotics,", "score": 0.20286961 }, { "number": 14, "title": "From theory to practice: Revealing the real-world impact of ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)13794-2", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "by HDH Kariri · 2024 · Cited by 33 — Cognitive behavior therapy (CBT) is a proven treatment for many psychological disorders. It has been extensively studied and is effective for anxiety,", "score": 0.048212994 }, { "number": 15, "title": "Existing and emerging pharmacological approaches to the treatment of mania: A critical overview", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41398-022-01928-8", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "[11 and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–70.\")]. Additionally, combination treatment should be considered if no sufficient clinical response is observed after 1–2 weeks with therapeutic", "score": 0.31814662 }, { "number": 16, "title": "Screening for bipolar disorder in a tertiary mental health ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2666915321001414", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "by YS Liu · 2021 · Cited by 33 — MDQ is one of the most widely used self-report bipolar screening tools, with a demonstrated sensitivity and specificity of 66% (95% CI 57-73%) and 86% (95% CI", "score": 0.4882108 }, { "number": 17, "title": "Review Differential diagnosis of bipolar disorder and major ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0165032714700047", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "by RM Hirschfeld · 2014 · Cited by 304 — Several validated, easily administered screening instruments are available and can greatly improve the recognition of bipolar disorder in patients with", "score": 0.46147847 }, { "number": 18, "title": "Presentation, Clinical Course, and Diagnostic Assessment of ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/book/24609/chapter/187895759", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "The diagnostic challenge of differentiating bipolar depression from unipolar depression and the role of screening assessments is discussed.", "score": 0.44622982 }, { "number": 19, "title": "Screening for bipolar disorder in a Spanish sample of outpatients with current major depressive episode", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165032708002814", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Conclusions\n\nThe MDQ showed a positive screen rate for bipolar disorder in 24% of patients with a previous diagnosis of unipolar disorder and a current major depressive episode. Screening tools like MDQ could contribute to increase detection of bipolar disorder in patients with depression. Early", "score": 0.42634606 }, { "number": 20, "title": "Differential diagnosis of bipolar affective disorder type II and borderline personality disorder: analysis of the affective dimension", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0010440X12000454", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "neurovegetative depressive symptoms intercalated with euthymic periods facilitate a clear diagnosis of bipolarity. [...] ### Biol Psychiatry (2000) \n E. Irle _et al._\n### Reduced size and abnormal asymmetry of parietal cortex in women with borderline personality disorder\n\n### Biol Psychiatry (2005", "score": 0.3503997 }, { "number": 21, "title": "Treatment of bipolar disorder: a systematic review of available ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/11/7/999/787005", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by KN Fountoulakis · 2008 · Cited by 251 — Both first- and second-generation antipsychotics are efficacious in the treatment of acute mania. Quetiapine and the olanzapine–fluoxetine combination are also", "score": 0.37511167 }, { "number": 22, "title": "a CINP Task Force report based on a review of evidence", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/10/Supplement_1/S1/855835", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by N Sartorius · 2007 · Cited by 186 — Comorbidities or alternate diagnoses such as bipolar disorder may affect both the safety and efficacy of drug treatment.", "score": 0.3499997 }, { "number": 23, "title": "Pharmacological Augmentation in Unipolar Depression", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/23/9/587/5836840", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by RW Taylor · 2020 · Cited by 94 — Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. the prevention of relapse following electroconvulsive therapy:", "score": 0.32956484 }, { "number": 24, "title": "12 APPENDICES", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg185/documents/bipolar-disorder-update-draft-full-guideline-appendices-1102", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "can be found in 'The guidelines manual' (see ‘Further information’). 4.6 Status 4.6.1 Scope This is the final scope. 4.6.2 Timing The development of the guideline recommendations will begin in October 2012. DRAFT FOR CONSULTATION Bipolar Disorder (Update): full guideline (March 2014) 8 5 Related NIC", "score": 0.6410185 } ], "publishedAt": "2026-08-21T01:32:09.050523+00:00", "updatedAt": "2026-08-21T01:32:09.050523+00:00", "readingMinutes": 4, "slug": "bipolar-disorder" }